Largest pharmaceutical companies by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceutical companies ranked by total debt, at CHF 56.9B, ahead of Pfizer (CHF 54.6B) and Merck & Co (CHF 41.6B). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieCHF 56.9B
- Median
- CHF 4.4B
- Combined market value
- CHF 4.29T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | CHF 56.9B | CHF 428.6B | CHF 242.48 | 1.77% down | 26% up | ||
| 2 | PfizerPFE · Health Care | CHF 54.6B | CHF 135.5B | CHF 23.77 | 0.97% down | 14% up | ||
| 3 | Merck & CoMRK · Health Care | CHF 41.6B | CHF 287.8B | CHF 116.73 | 3.42% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | CHF 40.4B | CHF 558.9B | CHF 232.18 | 1.17% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | CHF 38B | CHF 103.7B | CHF 50.75 | 1.87% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | CHF 35.8B | CHF 1.05T | CHF 1,176.72 | 1.39% down | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | CHF 25.8B | CHF 57.6B | CHF 18.04 | 1.13% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | CHF 25B | CHF 235B | CHF 151.49 | 1.40% down | 2% up | ||
| 9 | NovartisNVS · Health Care | CHF 24.2B | CHF 248.4B | CHF 131.54 | 1.94% down | 25% up | ||
| 10 | SanofiSNY · Health Care | CHF 17.5B | CHF 95.8B | CHF 39.91 | 0.39% down | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | CHF 16.4B | CHF 147.3B | CHF 33.41 | 2.62% down | 17% down | ||
| 12 | GSKGSK · Health Care | CHF 16.2B | CHF 82.5B | CHF 41.15 | 0.85% down | 6% up | ||
| 13 | ViatrisVTRS · Health Care | CHF 12.1B | CHF 20B | CHF 17.42 | 1.05% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | CHF 10.9B | CHF 152.6B | CHF 88.10 | 0.19% down | 17% down | ||
| 15 | ZoetisZTS · Health Care | CHF 7.6B | CHF 29.2B | CHF 71.78 | 1.99% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | CHF 7.5B | CHF 33.6B | CHF 58.52 | 1.07% up | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | CHF 4.5B | CHF 13.4B | CHF 208.29 | 2.65% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | CHF 4.4B | CHF 26.8B | CHF 43.43 | 0.86% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | CHF 3.4B | CHF 11.4B | CHF 22.74 | 4.33% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | CHF 2.2B | CHF 6.5B | CHF 18.63 | 4.62% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | CHF 1.7B | CHF 12.8B | CHF 65.90 | 1.78% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | CHF 1.7B | CHF 82.7B | CHF 799.25 | 1.01% down | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | CHF 1.5B | CHF 3.9B | CHF 23.48 | 3.32% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | CHF 866.8M | CHF 39B | CHF 341.63 | 1.93% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | CHF 673.7M | CHF 15B | CHF 229.18 | 0.25% up | 28% up | ||
| 26 | InsmedINSM · Health Care | CHF 460.9M | CHF 22.3B | CHF 101.74 | 0.96% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 286.5M | CHF 8B | CHF 344.04 | 3.29% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | CHF 269M | CHF 2.7B | CHF 13.69 | 0.81% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | CHF 242.4M | CHF 6.1B | CHF 43.56 | 0.04% up | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | CHF 207.1M | CHF 8.4B | CHF 55.71 | 5.38% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | CHF 187.9M | CHF 4.1B | CHF 23.78 | 1.29% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | CHF 163.3M | CHF 10.6B | CHF 12.69 | 1.75% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | CHF 158.3M | CHF 6B | CHF 113.50 | 0.96% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 91.2M | CHF 7B | CHF 101.24 | 2.99% up | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | CHF 34.2M | CHF 3.3B | CHF 24.39 | 1.51% down | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8430 CHF). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by total debt?
AbbVie (CHF 56.9B), Pfizer (CHF 54.6B) and Merck & Co (CHF 41.6B) are the top three of the 35 pharmaceutical companies ranked by total debt as of 18 Nov 2026, 18:41 UTC.
How many pharmaceutical companies are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 35 pharmaceutical companies ranked by total debt have a combined market value of CHF 4.29T as of 18 Nov 2026, 18:41 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.